Ramiven 150 mg Tablet

Abemaciclib belongs to a class of medications known as CDK4/6 inhibitors, which work by blocking specific proteins called cyclin-dependent kinases 4 and 6, which play a key role in helping cancer cells progress through the cell division cycle. By inhibiting these proteins, Abemaciclib helps slow down the uncontrolled growth and division of cancer cells. It is commonly used in combination with hormone therapy to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, offering an additional layer of cancer control beyond hormone therapy alone. Abemaciclib is also used as part of adjuvant treatment following surgery in certain early-stage breast cancers with a higher risk of recurrence, helping reduce the chance of the cancer returning. Unlike some other medications in its class, Abemaciclib can be taken continuously without a break period, offering a consistent treatment schedule. As an oral targeted therapy, it offers a convenient treatment option, allowing much of the treatment to take place at home between clinical check-ins. The tablets are typically taken twice daily, following a schedule established by an oncologist based on the patient's specific condition and treatment plan. Regular monitoring, including blood counts and liver function tests, is an important part of treatment to help track response and ensure safety. Many patients experience meaningful disease control and improved outcomes as part of a comprehensive treatment plan involving Abemaciclib. As with all targeted cancer therapies, Abemaciclib tablets should be used strictly under the guidance of an experienced oncology healthcare provider.